Advertisement

Topics

Magenta in-licenses Novartis' HSC835 UCB stem cell therapy candidate

15:40 EDT 4 May 2017 | Elsevier Business Intelligence

Concurrent with completing a GV-led $50mm Series B round, stem cell therapies start-up Magenta Therapeutics Inc. in-licensed ...

Original Article: Magenta in-licenses Novartis' HSC835 UCB stem cell therapy candidate

NEXT ARTICLE

More From BioPortfolio on "Magenta in-licenses Novartis' HSC835 UCB stem cell therapy candidate"

Quick Search
Advertisement
 

Relevant Topics

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...